AstraZeneca spins off autoimmune drugs into new biotech company
AstraZeneca is spinning off six early-stage experimental drugs into a new US$250 million standalone biotech company focused on severe autoimmune diseases.
from Latest News http://ift.tt/2GM6Umj
from Latest News http://ift.tt/2GM6Umj
Comments
Post a Comment